Database : MEDLINE
Search on : Diabetic and Angiopathies [Words]
References found : 17572 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1758 go to page                         

  1 / 17572 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 27771154
[Au] Autor:Barbieri M; Marfella R; Esposito A; Rizzo MR; Angellotti E; Mauro C; Siniscalchi M; Chirico F; Caiazzo P; Furbatto F; Bellis A; D'Onofrio N; Vitiello M; Ferraraccio F; Paolisso G; Balestrieri ML
[Ad] Address:Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, Second University of Naples, Piazza Miraglia 2, 80138, Naples, Italy. Electronic address: michelangela.barbieri@unina2.it.
[Ti] Title:Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.
[So] Source:J Diabetes Complications;31(2):295-303, 2017 Feb.
[Is] ISSN:1873-460X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIMS: Glucagon like peptide 1 (GLP-1) analogues and dipeptidyl peptidase IV (DPP-4) inhibitors reduce atherosclerosis progression in type 2 diabetes mellitus (T2DM) patients and are associated with morphological and compositional characteristics of stable plaque phenotype. GLP-1 promotes the secretion of adiponectin which exerts anti-inflammatory effects through the adaptor protein PH domain and leucine zipper containing 1 (APPL1). The potential role of APPL1 expression in the evolution of atherosclerotic plaque in TDM2 patients has not previously evaluated. METHODS: The effect of incretin therapy in the regulation of adiponectin/APPL1 signaling was evaluated both on carotid plaques of asymptomatic diabetic (n=71) and non-diabetic patients (n=52), and through in vitro experiments on endothelial cell (EC). RESULTS: Atherosclerotic plaques of T2DM patients showed lower adiponectin and APPL1 levels compared with non-diabetic patients, along with higher oxidative stress, tumor necrosis factor-α (TNF-α), vimentin, and matrix metalloproteinase-9 (MMP-9) levels. Among T2DM subjects, current incretin-users presented higher APPL1 and adiponectin content compared with never incretin-users. Similarly, in vitro observations on endothelial cells co-treated with high-glucose (25mM) and GLP-1 (100nM) showed a greater APPL1 protein expression compared with high-glucose treatment alone. CONCLUSIONS: Our findings suggest a potential role of adiponectin/APPL1 signaling in mediating the effect of incretin in the prevention of atherosclerosis progression or plaque vulnerability in T2DM.
[Mh] MeSH terms primary: Adaptor Proteins, Signal Transducing/agonists
Adiponectin/metabolism
Diabetes Mellitus, Type 2/drug therapy
Diabetic Angiopathies/prevention & control
Incretins/therapeutic use
Plaque, Atherosclerotic/prevention & control
Signal Transduction/drug effects
[Mh] MeSH terms secundary: Adaptor Proteins, Signal Transducing/metabolism
Aged
Anti-Inflammatory Agents, Non-Steroidal/pharmacology
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Antioxidants/pharmacology
Antioxidants/therapeutic use
Carotid Stenosis/complications
Carotid Stenosis/epidemiology
Carotid Stenosis/prevention & control
Carotid Stenosis/surgery
Cells, Cultured
Diabetes Mellitus, Type 2/complications
Diabetes Mellitus, Type 2/metabolism
Diabetes Mellitus, Type 2/pathology
Diabetic Angiopathies/epidemiology
Diabetic Angiopathies/pathology
Diabetic Angiopathies/surgery
Endarterectomy, Carotid
Endothelium, Vascular/drug effects
Endothelium, Vascular/immunology
Endothelium, Vascular/metabolism
Endothelium, Vascular/pathology
Female
Glucagon-Like Peptide 1/metabolism
Humans
Incretins/pharmacology
Italy/epidemiology
Male
Oxidative Stress/drug effects
Plaque, Atherosclerotic/complications
Plaque, Atherosclerotic/epidemiology
Plaque, Atherosclerotic/pathology
Risk Factors
Secondary Prevention
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Name of substance:0 (ADIPOQ protein, human); 0 (APPL1 protein, human); 0 (Adaptor Proteins, Signal Transducing); 0 (Adiponectin); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antioxidants); 0 (Incretins); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  2 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29442454
[Au] Autor:Grzelka A; Naskret D; Araszkiewicz A; Uruska A; Wegner M; Zozulinska-Ziólkiewicz D
[Ad] Address:Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poland.
[Ti] Title:Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznan Prospective Study.
[So] Source:Adv Clin Exp Med;26(9):1343-1349, 2017 Dec.
[Is] ISSN:1899-5276
[Cp] Country of publication:Poland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Osteoprotegerin (OPG) is an arterial calcification marker which has been associated with vascular damage. Elevated OPG concentrations associated with low-grade inflammatory processes are found in diabetic subjects. OBJECTIVES: The aim of the study was to assess concentrations of OPG in relation to the presence of diabetic complications in patients with diabetes type 1 (DM 1) participating in the Poznan Prospective Study (PoProStu). MATERIAL AND METHODS: The study included 74 patients with DM1 (48 men) with a median age of 39 years (interquartile range [IQR]: 34-43) and a median 15-year history (IQR: 14-16) of diabetes, who were participants in the PoProStu. Serum OPG concentration was measured using the ELISA method, and serum concentration of C-reactive protein was measured with a high sensitivity test (hsCRP). The visceral adipose index (VAI) was used to determine indirect markers of insulin resistance (IR). The prevalence of microangiopathic diabetes complications was assessed. RESULTS: Retinopathy was diagnosed in 28 patients (38%), diabetic kidney disease (DKD) in 28 (38%) patients, and neuropathy in 17 (23%) patients. The median OPG level was 43.8 (28.0-74.0) pg/mL. Patients with retinopathy had higher levels of OPG than those without retinopathy: 47.5 (35.0-88.0) vs 35.4 (24.7-69.4) pg/mL (p = 0.04). Positive correlations were observed between OPG concentration and hsCRP (Rs = 0.53; p < 0.001), HbA1c level (Rs = 0.36; p = 0.002), VAI (Rs = 0.23; p = 0.04) and waist circumference (Rs = 0.24; p = 0.04). CONCLUSIONS: Higher concentrations of osteoprotegerin in DM1 patients are related to the presence of retinopathy. The study results indicate that OPG might play a role in the pathogenesis of vascular complications in association with hyperglycemia and low-grade inflammatory processes.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180214
[Lr] Last revision date:180214
[St] Status:In-Data-Review
[do] DOI:10.17219/acem/65072

  3 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27770590
[Au] Autor:Cho YH; Craig ME; Januszewski AS; Benitez-Aguirre P; Hing S; Jenkins AJ; Donaghue KC
[Ad] Address:Institute of Endocrinology and Diabetes, Children's Hospital at Westmead, Westmead, Australia.
[Ti] Title:Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications.
[So] Source:Diabet Med;34(4):543-550, 2017 Apr.
[Is] ISSN:1464-5491
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:AIM: To test the hypothesis that non-invasive skin autofluorescence, a measure of advanced glycation end products, would provide a surrogate measure of long-term glycaemia and be associated with early markers of microvascular complications in adolescents with Type 1 diabetes. METHODS: Forearm skin autofluorescence (arbitrary units) was measured in a cross-sectional study of 135 adolescents with Type 1 diabetes [mean ± sd age 15.6 ± 2.1 years, diabetes duration 8.7 ± 3.5 years, HbA 72 ± 16 mmol/mol (8.7 ± 1.5%)]. Retinopathy, assessed using seven-field stereoscopic fundal photography, was defined as ≥1 microaneurysm or haemorrhage. Cardiac autonomic function was measured by standard deviation of consecutive RR intervals on a 10-min continuous electrocardiogram recording, as a measure of heart rate variability. RESULTS: Skin autofluorescence was significantly associated with age (R = 0.15; P < 0.001). Age- and gender-adjusted skin autofluorescence was associated with concurrent HbA (R = 0.32; P < 0.001) and HbA over the previous 2.5-10 years (R = 0.34-0.43; P < 0.002). Age- and gender-adjusted mean skin autofluorescence was higher in adolescents with retinopathy vs those without retinopathy [mean 1.38 (95% CI 1.29, 1.48) vs 1.22 (95% CI 1.17, 1.26) arbitrary units; P = 0.002]. In multivariable analysis, retinopathy was significantly associated with skin autofluorescence, adjusted for duration (R = 0.19; P = 0.03). Cardiac autonomic dysfunction was also independently associated with skin autofluorescence (R = 0.11; P = 0.006). CONCLUSIONS: Higher skin autofluorescence is associated with retinopathy and cardiac autonomic dysfunction in adolescents with Type 1 diabetes. The relationship between skin autofluorescence and previous glycaemia may provide insight into metabolic memory. Longitudinal studies will determine the utility of skin autofluorescence as a non-invasive screening tool to predict future microvascular complications.
[Mh] MeSH terms primary: Diabetes Mellitus, Type 1/physiopathology
Diabetic Angiopathies/diagnostic imaging
Diabetic Retinopathy/diagnostic imaging
Microaneurysm/diagnostic imaging
Retinal Hemorrhage/diagnostic imaging
Skin/diagnostic imaging
[Mh] MeSH terms secundary: Adolescent
Autonomic Nervous System Diseases/etiology
Autonomic Nervous System Diseases/physiopathology
Diabetes Mellitus, Type 1/complications
Diabetes Mellitus, Type 1/metabolism
Diabetic Angiopathies/etiology
Diabetic Angiopathies/physiopathology
Diabetic Retinopathy/etiology
Diabetic Retinopathy/physiopathology
Electrocardiography
Female
Fundus Oculi
Glycated Hemoglobin A/metabolism
Heart Rate
Humans
Male
Microaneurysm/etiology
Microaneurysm/physiopathology
Multivariate Analysis
Optical Imaging
Retinal Hemorrhage/etiology
Retinal Hemorrhage/physiopathology
Skin/blood supply
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Glycated Hemoglobin A); 0 (hemoglobin A1c protein, human)
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[Js] Journal subset:IM
[Da] Date of entry for processing:161023
[St] Status:MEDLINE
[do] DOI:10.1111/dme.13280

  4 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29275569
[Au] Autor:Ren XY; Wang C; Liu X; Li H; Gao JH; Ge XJ
[Ad] Address:Department of Periodontology, Shanxi Medical University, Taiyuan 030001, China.
[Ti] Title:[Establishment of rat model with diabetes mellitus and concomitant periodontitis and the carotid artery lesions in the model rats].
[So] Source:Zhonghua Kou Qiang Yi Xue Za Zhi;52(12):747-752, 2017 Dec 09.
[Is] ISSN:1002-0098
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:To establish SD rat model with type 2 diabetes mellitus (DM) and concomitant chronic periodontitis (CP) and to evaluate the influence of periodontitis on the vascular lesions of type 2 diabetes rats. Totally 241 clean level SD rats were randomly divided into four groups, group A (normal control, NC, 27), group B (DM, 34), group C (CP, 90) and group D (DM+CP, 90). The rats of DM group were fed with high-fat and high-sugar diet for 8 to 10 weeks, and then were multiply injected with small dose streptozotocin under the condition of ice bath. Blood sugar levels after the injection were dynamically monitored at 72 h, 1 week, 2 weeks and 4 weeks, respectively. The CP model was established by means of ligation. Bilateral maxillary first and second molars were selected and ligated using 0.2 mm orthodontic wires binding with 4-0 surgical suture soaked with (Pg) suspension. After a period of 14 weeks, all the rats were put to death. Maxillary samples were subjected to methylene blue staining to observe alveolar bone loss. Bilateral carotid artery specimens were collected. The left carotid artery specimens were used to detect the prevalence of Pg using quantitative real-time PCR. The right carotid artery specimens were used to observe pathological changes. Blood sugar levels of rats in group B and D increased and changed sharply after Streptozotocin injection with in 1 week. Symptoms of 'more drink, more food and body weight loss' appeared. The fasting blood glucose (FBG) was more than 7.8 mmol/L and (or) the random blood glucose (RBG) was more than 17.8 mmol/L. Both FBG and RBG became stable after 2 to 3 weeks. Levels of HbA1C in group B and D ([7.32±0.45]%, [9.41±0.45]%) were significantly higher than that of group A ([4.02±0.45]%) ( 0.01). Rats of group D were observed the most severe bone loss showing wider interdental space and furcation involvement. Pathological results of carotid artery tissues of group D showed the worst lesions including thinning and calcification of vessel walls, and breaking down or disappearance of elastic fibers. The prevalences of DNA of Pg in groups of A, B, C and D were 3/7, 3/7, 6/7 and 7/7, respectively. The bacteria numbers detected by quantitative real-time PCR in groups C and D were significantly higher than that of groups A and B ( 0.01). Rat model of type 2 DM with periodontitis was successfully established in the present study. Carotid artery specimens from DM+CP model rats showed typical vascular lesions such as calcification and fiber disorders. Pg was found in all carotid specimens and the highest bacteria numbers were detected in the composite model rats. The Pg might play a role in the progress of diabetes vascular lesions.
[Mh] MeSH terms primary: Carotid Arteries/pathology
Carotid Artery Diseases/pathology
Chronic Periodontitis/pathology
Diabetes Mellitus, Experimental/pathology
Diabetes Mellitus, Type 2/pathology
[Mh] MeSH terms secundary: Alveolar Bone Loss/diagnosis
Alveolar Bone Loss/pathology
Animals
Blood Glucose/analysis
Carotid Arteries/microbiology
Carotid Artery Diseases/microbiology
Chronic Disease
Chronic Periodontitis/microbiology
Diabetes Mellitus, Experimental/chemically induced
Diabetes Mellitus, Type 2/chemically induced
Disease Progression
Glycated Hemoglobin A/metabolism
Maxilla
Porphyromonas gingivalis
Random Allocation
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Blood Glucose); 0 (Glycated Hemoglobin A)
[Em] Entry month:1802
[Cu] Class update date: 180209
[Lr] Last revision date:180209
[Js] Journal subset:D; IM
[Da] Date of entry for processing:171226
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1002-0098.2017.12.007

  5 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28467200
[Au] Autor:Santesson P; Lins PE; Kalani M; Adamson U; Lelic I; von Wendt G; Fagrell B; Jörneskog G
[Ad] Address:1 Microcirculatory Laboratory, Division of Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
[Ti] Title:Skin microvascular function in patients with type 1 diabetes: An observational study from the onset of diabetes.
[So] Source:Diab Vasc Dis Res;14(3):191-199, 2017 May.
[Is] ISSN:1752-8984
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: The development of disturbances in skin microcirculation in type 1 diabetes is not well characterised. We assessed skin microcirculation longitudinally from the onset of diabetes up to 29 years of duration to investigate when such disturbances start. MATERIAL AND METHODS: Seventeen adult patients with type 1 diabetes participated. Skin microvascular function in digit IV of the left hand was investigated by laser Doppler fluxmetry (LDF, arbitrary units [AU]). LDF was carried out at rest and following one-min arterial occlusion. Time to peak LDF (s) and percentage increase of LDF (post-occlusive reactive hyperaemia, PRH%) were determined. Retinopathy was assessed from fundus photographs or ophthalmoscopic recordings. RESULTS: Skin microvascular function remained normal during the first five years. Compared with baseline and a non-diabetic reference group, time to peak LDF was prolonged after 7-9 years of diabetes ( p < 0.01). PRH% was lower than in the reference group after 7-9 years ( p < 0.01), and lower than baseline after 24-29 years of diabetes ( p < 0.05). All but one patient developed retinopathy and the first signs were found after 10 years of diabetes. CONCLUSIONS: Functional disturbances in total skin microcirculation were observed after seven years in patients with type 1 diabetes and preceded diabetic complications such as retinopathy.
[Mh] MeSH terms primary: Diabetes Mellitus, Type 1/complications
Diabetic Angiopathies/etiology
Microcirculation
Microvessels/physiopathology
Skin/blood supply
[Mh] MeSH terms secundary: Adult
Blood Flow Velocity
Case-Control Studies
Diabetes Mellitus, Type 1/diagnosis
Diabetes Mellitus, Type 1/physiopathology
Diabetic Angiopathies/diagnosis
Diabetic Angiopathies/physiopathology
Diabetic Neuropathies/diagnosis
Diabetic Neuropathies/etiology
Diabetic Retinopathy/diagnosis
Diabetic Retinopathy/etiology
Disease Progression
Female
Humans
Laser-Doppler Flowmetry
Longitudinal Studies
Male
Middle Aged
Ophthalmoscopy
Prospective Studies
Regional Blood Flow
Risk Factors
Skin Temperature
Time Factors
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Entry month:1712
[Cu] Class update date: 171219
[Lr] Last revision date:171219
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1177/1479164117694463

  6 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28467198
[Au] Autor:Ng HH; Yildiz GS; Ku JM; Miller AA; Woodman OL; Hart JL
[Ad] Address:1 School of BioSciences, University of Melbourne, Parkville, VIC, Australia.
[Ti] Title:Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic mice.
[So] Source:Diab Vasc Dis Res;14(3):246-253, 2017 May.
[Is] ISSN:1752-8984
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Hydrogen sulphide (H S) is endogenously produced in vascular tissue and has anti-oxidant and vasoprotective properties. This study investigates whether chronic treatment using the fast H S donor NaHS could elicit a vasoprotective effect in diabetes. Diabetes was induced in male C57BL6/J mice with streptozotocin (60 mg/kg daily, ip for 2 weeks) and confirmed by elevated blood glucose and glycated haemoglobin levels. Diabetic mice were then treated with NaHS (100 µmol/kg/day) for 4 weeks, and aortae collected for functional and biochemical analyses. In the diabetic group, both endothelium-dependent vasorelaxation and basal nitric oxide (NO ) bioactivity were significantly reduced ( p < 0.05), and maximal vasorelaxation to the NO donor sodium nitroprusside was impaired ( p < 0.05) in aorta compared to control mice. Vascular superoxide generation via nicotine adenine dinucleotide phosphate (NADPH) oxidase ( p < 0.05) was elevated in aorta from diabetic mice which was associated with increased expression of NOX2 ( p < 0.05). NaHS treatment of diabetic mice restored endothelial function and exogenous NO efficacy back to control levels. NaHS treatment also reduced the diabetes-induced increase in NADPH oxidase activity, but did not affect NOX2 protein expression. These data show that chronic NaHS treatment reverses diabetes-induced vascular dysfunction by restoring NO efficacy and reducing superoxide production in the mouse aorta.
[Mh] MeSH terms primary: Antioxidants/administration & dosage
Diabetes Mellitus, Experimental/drug therapy
Diabetic Angiopathies/prevention & control
Endothelium, Vascular/drug effects
Oxidative Stress/drug effects
Sulfides/administration & dosage
[Mh] MeSH terms secundary: Animals
Blood Glucose/metabolism
Diabetes Mellitus, Experimental/blood
Diabetes Mellitus, Experimental/complications
Diabetic Angiopathies/etiology
Diabetic Angiopathies/metabolism
Diabetic Angiopathies/physiopathology
Dose-Response Relationship, Drug
Drug Administration Schedule
Endothelium, Vascular/metabolism
Endothelium, Vascular/physiopathology
Glycated Hemoglobin A/metabolism
Male
Mice, Inbred C57BL
Muscle, Smooth, Vascular/drug effects
Muscle, Smooth, Vascular/metabolism
Muscle, Smooth, Vascular/physiopathology
NADPH Oxidase 2/metabolism
Nitric Oxide/metabolism
Nitric Oxide Donors/pharmacology
Nitric Oxide Synthase Type III/metabolism
Superoxides/metabolism
Time Factors
Vasodilation/drug effects
Vasodilator Agents/pharmacology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antioxidants); 0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (HbA(1c) protein, mouse); 0 (Nitric Oxide Donors); 0 (Sulfides); 0 (Vasodilator Agents); 11062-77-4 (Superoxides); 31C4KY9ESH (Nitric Oxide); EC 1.14.13.39 (Nitric Oxide Synthase Type III); EC 1.14.13.39 (Nos3 protein, mouse); EC 1.6.3.- (Cybb protein, mouse); EC 1.6.3.- (NADPH Oxidase 2); FWU2KQ177W (sodium bisulfide)
[Em] Entry month:1712
[Cu] Class update date: 171219
[Lr] Last revision date:171219
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1177/1479164117692766

  7 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28467197
[Au] Autor:Wu HT; Lee KW; Pan WY; Liu AB; Sun CK
[Ad] Address:1 Department of Electrical Engineering, National Dong Hwa University, Hualien, Taiwan, R.O.C.
[Ti] Title:Difference in bilateral digital volume pulse as a novel non-invasive approach to assessing arteriosclerosis in aged and diabetic subjects: A preliminary study.
[So] Source:Diab Vasc Dis Res;14(3):254-257, 2017 May.
[Is] ISSN:1752-8984
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: This study aimed at validating photoplethysmography for assessing bilateral blood pressure differences through investigating the correlations of digital volume pulse with arteriosclerosis risk. METHODS: Totally, 111 subjects (70 healthy and 41 diabetic) were recruited. Demographic, blood pressure and anthropometric data were recorded. Blood was collected for determining serum cholesterol, total triglyceride, total cholesterol, high-/low-density lipoprotein cholesterol, fasting blood sugar and glycated haemoglobin concentrations. Arterial stiffness was assessed with electrocardiogram-based pulse wave velocity, crest time and inter-digital volume pulse differences. RESULTS: Receiver operating characteristic curve demonstrated high inter-digital volume pulse difference sensitivity to glycated haemoglobin level over 6.5%. Linear regression analysis demonstrated significant correlation between inter-digital volume pulse difference and electrocardiogram-based pulse wave velocity ( r = 0.692, p < 0.001). Compared with electrocardiogram-based pulse wave velocity, inter-digital volume pulse difference exhibited highly significant correlations with age, glycated haemoglobin level, pulse pressure, total cholesterol/high-density lipoprotein ratio, crest time, high-density lipoprotein and systolic blood pressure (all ps < 0.001). CONCLUSION: In conclusion, the results not only demonstrated successful application of a novel non-invasive waveform contour index, inter-digital volume pulse difference, in differentiating young from aged subjects and patients with good diabetic control from those with poor diabetic control but also validated its use in identifying arteriosclerosis risks. The results, therefore, endorse its domestic application as non-invasive tool for arteriosclerosis risk screening.
[Mh] MeSH terms primary: Atherosclerosis/diagnosis
Blood Pressure
Diabetic Angiopathies/diagnosis
Fingers/blood supply
Photoplethysmography
[Mh] MeSH terms secundary: Adult
Age Factors
Area Under Curve
Atherosclerosis/blood
Atherosclerosis/physiopathology
Biomarkers/blood
Blood Glucose/analysis
Case-Control Studies
Diabetic Angiopathies/blood
Diabetic Angiopathies/physiopathology
Glycated Hemoglobin A/analysis
Humans
Linear Models
Lipids/blood
Pilot Projects
Predictive Value of Tests
Preliminary Data
Pulse Wave Analysis
ROC Curve
Reproducibility of Results
Vascular Stiffness
Young Adult
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Name of substance:0 (Biomarkers); 0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Lipids); 0 (hemoglobin A1c protein, human)
[Em] Entry month:1712
[Cu] Class update date: 171219
[Lr] Last revision date:171219
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1177/1479164116688870

  8 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28749197
[Au] Autor:Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
[Ad] Address:a Cardiology Division, Department of Medicine , Westchester Medical Center /New York Medical College , Valhalla , NY , USA.
[Ti] Title:Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
[So] Source:Postgrad Med;129(8):811-821, 2017 Nov.
[Is] ISSN:1941-9260
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Diabetes mellitus is a growing in exponential proportions. If the current growth trend continues, it may result in every third adult in the United States having diabetes mellitus by 2050, and every 10 adult worldwide. Type 2 diabetes mellitus (T2DM) confers a 2- to 3-fold increased risk of cardiovascular (CV) events compared with non-diabetic patients, and CV mortality is responsible for around 80% mortality in this population. Patients with T2DM can have other features of insulin resistance-metabolic syndrome like hypertension, lipid abnormalities, and obesity which are all associated with increased CV disease and stroke risk even in the absence of T2DM. The management of a T2DM calls for employing a holistic risk factor control approach. Metformin is the first line therapy for T2DM and has been shown to have cardiovascular beneficial effects. Intense debate regarding the risk of myocardial infarction with rosiglitazone led to regulatory agencies necessitating cardiovascular outcome trials with upcoming anti-diabetic medications. Glucagon like peptide-1 agonists and sodium glucose co-transporter-2 inhibitors have shown promising CV safety and additional CV benefit in recent clinical trials. These drugs have favorable effects on traditional CV risk factors. The findings from these studies further support that fact that CV risk factor control plays an important role in reducing morbidity and mortality in T2DM patients. This review article will discuss briefly the cardiovascular safety and benefits of the oral medications which are currently being used for T2DM and will then discuss in detail about the newer medications being investigated for the treatment of T2DM.
[Mh] MeSH terms primary: Cardiovascular Diseases/etiology
Cardiovascular Diseases/prevention & control
Diabetes Mellitus, Type 2/complications
Diabetes Mellitus, Type 2/drug therapy
Hypoglycemic Agents/therapeutic use
[Mh] MeSH terms secundary: Benzamides/therapeutic use
Diabetic Angiopathies/prevention & control
Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
Glucagon-Like Peptide-1 Receptor/agonists
Glycoside Hydrolase Inhibitors/therapeutic use
Humans
Hypoglycemic Agents/administration & dosage
Hypoglycemic Agents/adverse effects
Metformin/therapeutic use
Randomized Controlled Trials as Topic
Risk Factors
Sodium-Glucose Transporter 2/antagonists & inhibitors
Sulfonylurea Compounds/therapeutic use
Thiazolidinediones/therapeutic use
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Benzamides); 0 (Dipeptidyl-Peptidase IV Inhibitors); 0 (Glucagon-Like Peptide-1 Receptor); 0 (Glycoside Hydrolase Inhibitors); 0 (Hypoglycemic Agents); 0 (Sodium-Glucose Transporter 2); 0 (Sulfonylurea Compounds); 0 (Thiazolidinediones); 8V6OK1I088 (meglitinide); 9100L32L2N (Metformin)
[Em] Entry month:1711
[Cu] Class update date: 171128
[Lr] Last revision date:171128
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170728
[St] Status:MEDLINE
[do] DOI:10.1080/00325481.2017.1358064

  9 / 17572 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28436035
[Au] Autor:D'Amico AG; Maugeri G; Rasà DM; La Cognata V; Saccone S; Federico C; Cavallaro S; D'Agata V
[Ad] Address:Department of Human Science and Promotion of Quality of Life, San Raffaele Open University of Rome, Italy.
[Ti] Title:NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression.
[So] Source:J Cell Physiol;233(2):1120-1128, 2018 Feb.
[Is] ISSN:1097-4652
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Diabetic macular edema (DME) is a common complication leading to a central vision loss in patients with diabetes. In this eye pathology, the hyperglycaemic/hypoxic microenvironment of pigmented epithelium is responsible for outer blood retinal barrier integrity changes. More recently, we have shown that a small peptide derived from the activity-dependent neuroprotective protein (ADNP), known as NAP, counteracts damages occurring during progression of diabetic retinopathy by modulating HIFs/VEGF pathway. Here, we have investigated for the first time the role of this peptide on outer blood retinal barrier (BRB) integrity exposed to hyperglycaemic/hypoxic insult mimicking a model in vitro of DME. To characterize NAP role on disease's pathogenesis, we have analyzed its effect on HIFs/VEGF system in human retinal pigmented epithelial cells, ARPE-19, grown in high glucose and low oxygen tension. The results have shown that NAP prevents outer BRB breakdown by reducing HIF1α/HIF2α, VEGF/VEGFRs, and increasing HIF3α expression, moreover it is able to reduce the percentage of apoptotic cells by modulating the expression of two death related genes, BAX and Bcl2. Further investigations are needed to determine the possible use of NAP in DME treatment.
[Mh] MeSH terms primary: Basic Helix-Loop-Helix Transcription Factors/metabolism
Blood-Retinal Barrier/drug effects
Diabetic Angiopathies/drug therapy
Epithelial Cells/drug effects
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
Macular Edema/drug therapy
Oligopeptides/pharmacology
Retinal Pigment Epithelium/drug effects
Vascular Endothelial Growth Factor A/metabolism
[Mh] MeSH terms secundary: Apoptosis/drug effects
Blood-Retinal Barrier/metabolism
Blood-Retinal Barrier/pathology
Cell Hypoxia
Cell Line
Cytoprotection
Diabetic Angiopathies/metabolism
Diabetic Angiopathies/pathology
Electric Impedance
Epithelial Cells/metabolism
Epithelial Cells/pathology
Glucose/metabolism
Humans
Macular Edema/metabolism
Macular Edema/pathology
Proto-Oncogene Proteins c-bcl-2/metabolism
Receptors, Vascular Endothelial Growth Factor/metabolism
Retinal Pigment Epithelium/metabolism
Retinal Pigment Epithelium/pathology
Signal Transduction/drug effects
bcl-2-Associated X Protein/metabolism
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (BAX protein, human); 0 (BCL2 protein, human); 0 (Basic Helix-Loop-Helix Transcription Factors); 0 (HIF1A protein, human); 0 (HIF3A protein, human); 0 (Hypoxia-Inducible Factor 1, alpha Subunit); 0 (Oligopeptides); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 0 (bcl-2-Associated X Protein); 0 (endothelial PAS domain-containing protein 1); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); GF00K3IIWE (davunetide); IY9XDZ35W2 (Glucose)
[Em] Entry month:1711
[Cu] Class update date: 171128
[Lr] Last revision date:171128
[Js] Journal subset:IM
[Da] Date of entry for processing:170425
[St] Status:MEDLINE
[do] DOI:10.1002/jcp.25971

  10 / 17572 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29059687
[Au] Autor:Conlin PR; Colburn J; Aron D; Pries RM; Tschanz MP; Pogach L
[Ad] Address:From VA Boston Healthcare System, West Roxbury, Massachusetts; San Antonio Military Medical Center, Fort Sam Houston, Texas; Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio; VHA National Center for Health Promotion and Disease Prevention, Durham, North Carolina; San Diego Internal Medicine
[Ti] Title:Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
[So] Source:Ann Intern Med;167(9):655-663, 2017 Nov 07.
[Is] ISSN:1539-3704
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Description: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. Methods: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.
[Mh] MeSH terms primary: Diabetes Mellitus, Type 2/therapy
[Mh] MeSH terms secundary: Biomarkers/blood
Blood Glucose/metabolism
Clinical Decision-Making
Decision Making
Diabetes Mellitus, Type 2/blood
Diabetes Mellitus, Type 2/complications
Diabetic Angiopathies/prevention & control
Fructosamine/blood
Glycated Hemoglobin A/metabolism
Humans
Hypoglycemic Agents/therapeutic use
Life Expectancy
Patient Preference
Patient-Centered Care
[Pt] Publication type:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Name of substance:0 (Biomarkers); 0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 4429-04-3 (Fructosamine)
[Em] Entry month:1711
[Cu] Class update date: 171116
[Lr] Last revision date:171116
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171024
[St] Status:MEDLINE
[do] DOI:10.7326/M17-1362


page 1 of 1758 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information